 Axonics Modulation Technologies, Inc. NASDAQ: AXNX, a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation SNM devices for the treatment of urinary and bowel dysfunction, today announced completion of 2-year follow-ups and topline clinical results from its ARTISAN-SNM pivotal study that was conducted to evaluate the safety and efficacy of the Axonics r-SNM System. 